To receive a screening test for hepatitis virus B (HBV) and C (HCV) is one of the top priorities for liver cancer prevention in Japan. The aim of this study is to clarify the factors, which affect the decision of acceptance or refusal the HBV (cid:2) HCV screening test, and we conducted a survey in the form of a questionnaire. Of the 447 subjects who received the annual health check-up, 373 subjects accepted the additional HBV (cid:2) HCV screening test according to the information of mortality rate of liver cancer and benefit of anti-virus therapy whereas 74 subjects refused according to no intent to take anti-virus therapy for economical reasons and saw themselves as outside of HBV (cid:2) HCV infection. Results indicated that meaning information about natural history of viral hepatitis and liver cancer prevention could contribute to the improvement of consultation rate of screening test for HBV & HCV.